Ensysce to present overdose protection program at NIH HEAL Meeting

Ensysce Biosciences announced a Poster Presentation will be presented by Geoff Birkett, Chief Commercial Officer of Ensysce, at the Annual NIH HEAL Meeting on February 22, 2023, in Washington, D.C. The HEAL initiative is an effort to improve prevention and treatment strategies for opioid misuse and addiction and to enhance pain management across NIH institutes. The HEAL Annual meeting is designed to bring together researchers, federal officials, people with life experience, and other stakeholders to share research findings, explore trends and shared interests, and ultimately to identify opportunities to advance the goals of the initiative. The meeting will include panels, scientific symposia, discussion groups, networking, and poster sessions for in-person and virtual attendees. Ensysce will present its work on the overdose protection platform, MPAR that has been supported by the HEAL program. The clinical development of PF614-MPAR, the first opioid drug product that has both abuse deterrent properties as well as overdose protection, is a direct result of the efforts of this support. PF614-MPAR, designed to provide optimal pain relief at prescribed doses, has overdose protection built into each capsule.